Appian (NASDAQ:APPN – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Appian to post earnings of ($0.09) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Appian Stock Performance
NASDAQ:APPN opened at $36.82 on Tuesday. Appian has a one year low of $26.28 and a one year high of $42.17. The firm has a market cap of $2.66 billion, a P/E ratio of -24.71 and a beta of 1.57. The firm has a 50-day simple moving average of $32.68 and a 200-day simple moving average of $32.05.
Insider Activity at Appian
In other Appian news, major shareholder Abdiel Capital Advisors, Lp bought 150,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average cost of $27.11 per share, with a total value of $4,066,500.00. Following the acquisition, the insider now directly owns 8,255,847 shares of the company’s stock, valued at $223,816,012.17. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 1,044,276 shares of company stock valued at $31,165,851 over the last 90 days. 44.00% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on Appian
About Appian
Appian Corporation, a software company that provides low-code design platform in the United States, Mexico, Portugal, and internationally. The company's platform offers artificial intelligence, process automation, data fabric, and process mining. It provides The Appian Platform, an integrated automation platform that enables organizations to design, automate, and optimize mission-critical business processes.
Featured Stories
- Five stocks we like better than Appian
- How to Use the MarketBeat Dividend Calculator
- Intel: Is Now the Time to Be Brave?
- Why Are Stock Sectors Important to Successful Investing?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a buyback in stocks? A comprehensive guide for investors
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Appian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appian and related companies with MarketBeat.com's FREE daily email newsletter.